<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2858">
  <stage>Registered</stage>
  <submitdate>25/06/2010</submitdate>
  <approvaldate>25/06/2010</approvaldate>
  <nctid>NCT01175655</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation</studytitle>
    <scientifictitle>A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation</scientifictitle>
    <utrn />
    <trialacronym>MSC in OB</trialacronym>
    <secondaryid>EC 28105</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bronchiolitis Obliterans</healthcondition>
    <healthcondition>Lung Transplantation</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - MSC

Experimental: MSC - 


Other interventions: MSC
mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To establish the safety of infusions of MSC from related or unrelated HLA identical or HLA mismatched donors in the management of bronchiolitis obliterans syndrome after lung transplantation.</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To document changes in lung function and 6 minute walk distance (6MWD) following infusion of MSC</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To document survival post MSC infusion</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients with single, bilateral or heart-lung allografts

          2. Patients with bronchiolitis obliterans syndrome (BOS) grades 2 &amp; 3 (defined and graded
             according to international criteria (Appendix 1)), with evidence of deterioration in
             allograft function (i.e. deteriorating FEV1 or worsening BOS grade) within the last 12
             months.

          3. Patients with BOS grade 1 and evidence of deterioration in allograft function (i.e.
             deteriorating FEV1 or worsening BOS grade) within the last 12 months and at least one
             of the following additional risk factors for subsequent death:

               -  Single lung transplant

               -  Rapid deterioration (&gt;20% fall in FEV1 in the previous 12 months)

               -  A pre-transplant diagnosis of usual interstitial pneumonia (pulmonary fibrosis)
                  or pulmonary hypertension</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with active infection, acute allograft rejection, or airway anastomotic
             complications

          2. Patients with &gt; 3 infective exacerbations of BOS in the last 12 months

          3. Patients with a history of cytomegalovirus (CMV) pneumonitis

          4. Patients with poor performance status and/or not expected to survive 3 months

          5. Patients who are pregnant or breastfeeding

          6. Patients with an allergy to beef products.

          7. Any condition that in the opinion of the Investigator may interfere with the safety of
             the patient, his / her completion of required follow-up visits or evaluation of the
             study objectives.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,WA</recruitmentstate>
    <hospital>TPCH - Brisbane</hospital>
    <hospital>RPH - Perth</hospital>
    <postcode>4032 - Brisbane</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The Prince Charles Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cell &amp; Tissue Therapies Western Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of this study is to establish the safety of infusions of Mesenchymal Stromal
      Cells (MSC) from related or unrelated Human Leukocyte Antigen (HLA) identical or HLA
      mismatched donors in the management of bronchiolitis obliterans syndrome after lung
      transplantation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01175655</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniel Chambers, A/Prof</name>
      <address>The Prince Charles Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>